Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Recurrence 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Hodgkin Disease 1

Interventions

Specimen Handling 308Magnetic Resonance Spectroscopy 265pembrolizumab 254Carboplatin 185Cyclophosphamide 180Biopsy 168Cisplatin 157Gemcitabine 136Paclitaxel 131Bevacizumab 125fludarabine 118Nivolumab 111Radiotherapy 109Oxaliplatin 88Docetaxel 88Fluorouracil 85Capecitabine 84venetoclax 78Dexamethasone 77Pemetrexed 73Rituximab 70Leucovorin 69Drug Therapy 69durvalumab 67atezolizumab 67Radiosurgery 65Blood Specimen Collection 65Standard of Care 64Doxorubicin 64Radiation 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Hematopoietic Stem Cell Mobilization × 90 days × Clear all
NCT06724237 2026-05-15

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Eastern Cooperative Oncology Group

Phase 3 Recruiting
294 enrolled
Lymphoid

Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
257 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡